Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates

Nucleic Acids Research

Volumn 43, Issue 2, 2015, Pages 1189-1203

  Cuellar, Trinna L ^a   Barnes, Dwight ^a   Nelson, Christopher ^a   Tanguay, Joshua ^a   Yu, Shang Fan ^a   Wen, Xiaohui ^a   Scales, Suzie J ^a   Gesch, Julie ^a,e   Davis, David ^a,c   Van Brabant Smith, Anja ^b   Leake, Devin ^b,d   Vandlen, Richard ^a   Siebel, Christian W ^a  

^a GENENTECH INC   (United States)

^b Thermo Fisher Scientific   (United States)

^c Solazyme Inc   (United States)

^d Gen9 Inc   (United States)

^e HIGHLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; SMALL INTERFERING RNA;

ANIMAL; CELL LINE; CHEMISTRY; ENDOSOME; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; PROTEIN ENGINEERING; RNA INTERFERENCE;

ANIMALS; ANTIBODIES; CELL LINE; ENDOSOMES; MICE; NEOPLASMS; PROTEIN ENGINEERING; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84941072684     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gku1362     Document Type: Article

References (38)

1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
2. Davidson, B.L., McCray, P.B. Jr. (2011) Current prospects for RNA interference-based therapies. Nat. Rev. Genet., 12, 329-340.
3. Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-1070.
4. Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M. et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov., 3, 406-417.
5. Matsumura, Y., Oda, T., Maeda, H. (1987) General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Cancer Chemother., 14, 821-829.
6. Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A., Davis, M.E. (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A., 104, 15549-15554.
7. Cardoso, M.M., Peca, I.N., Roque, A.C. (2012) Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem., 19, 3103-3127.
8. Sievers, E.L., Senter, P.D. (2013) Antibody-drug conjugates in cancer therapy. Annu. Rev. Med., 64, 15-29.
9. Song, E., Zhu, P., Lee, S.K., Chowdhury, D., Kussman, S., Dykxhoorn, D.M., Feng, Y., Palliser, D., Weiner, D.B., Shankar, P. et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23, 709-717.
10. Kumar, P., Ban, H.S., Kim, S.S., Wu, H., Pearson, T., Greiner, D.L., Laouar, A., Yao, J., Haridas, V., Habiro, K. et al. (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell, 134, 577-586.
11. Yao, Y.D., Sun, T.M., Huang, S.Y., Dou, S., Lin, L., Chen, J.N., Ruan, J.B., Mao, C.Q., Yu, F.Y., Zeng, M.S. et al. (2012) Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med., 4, 130-148.
12. Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M., Lenox, J., Cerveny, C.G., Kissler, K.M., Bernhardt, S.X., Kopcha, A.K., Zabinski, R.F. et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res., 10, 7063-7070.
13. Junutula, J.R., Bhakta, S., Raab, H., Ervin, K.E., Eigenbrot, C., Vandlen, R., Scheller, R.H., Lowman, H.B. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods, 332, 41-52.
14. Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S. et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. bBotechnol., 26, 925-932.
15. Tan, M., Vernes, J.M., Chan, J., Cuellar, T.L., Asundi, A., Nelson, C., Yip, V., Shen, B., Vandlen, R., Siebel, C. et al. (2012) Real-time quantification of antibody-short interfering RNA conjugate in serum by antigen capture reverse transcription-polymerase chain reaction. Anal. Biochem., 430, 171-178.
16. Livak, K.J., Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
17. Sells, M.A., Li, J., Chernoff, J. (1995) Delivery of protein into cells using polycationic liposomes. BioTechniques, 19, 72-76, 78.
18. Scales, S.J., Gupta, N., Pacheco, G., Firestein, R., French, D.M., Koeppen, H., Rangell, L., Barry-Hamilton, V., Luis, E., Chuh, J. et al. (2014) An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol. Cancer Ther., 13, 2630-2640.
19. Chen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M.S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H. et al. (2007) Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res., 67, 4924-4932.
20. Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Blattler, W.A., Lambert, J.M., Chari, R.V., Lutz, R.J. et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res., 68, 9280-9290.
21. Austin, C.D., De Maziere, A.M., Pisacane, P.I., van Dijk, S.M., Eigenbrot, C., Sliwkowski, M.X., Klumperman, J., Scheller, R.H. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell, 15, 5268-5282.
22. Asundi, J., Reed, C., Arca, J., McCutcheon, K., Ferrando, R., Clark, S., Luis, E., Tien, J., Firestein, R., Polakis, P. (2011) An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin. Cancer Res., 17, 965-975.
23. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G., Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
24. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., Tuschl, T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563-574.
25. Dou, S., Yao, Y.D., Yang, X.Z., Sun, T.M., Mao, C.Q., Song, E.W., Wang, J. (2012) Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J. Controlled Release, 161, 875-883.
26. Lu, H., Wang, D., Kazane, S., Javahishvili, T., Tian, F., Song, F., Sellers, A., Barnett, B., Schultz, P.G. (2013) Site-specific antibody-polymer conjugates for siRNA delivery. J. Am. Chem. Soc., 135, 13885-13891.
27. Thiel, K.W., Hernandez, L.I., Dassie, J.P., Thiel, W.H., Liu, X., Stockdale, K.R., Rothman, A.M., Hernandez, F.J., McNamara, J.O. 2nd and Giangrande, P.H. (2012) Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res., 40, 6319-6337.
28. Lee, Y.S., Pressman, S., Andress, A.P., Kim, K., White, J.L., Cassidy, J.J., Li, X., Lubell, K., Lim do, H., Cho, I.S. et al. (2009) Silencing by small RNAs is linked to endosomal trafficking. Nat. Cell Biol., 11, 1150-1156.
29. Erickson, H.K., Park, P.U., Widdison, W.C., Kovtun, Y.V., Garrett, L.M., Hoffman, K., Lutz, R.J., Goldmacher, V.S., Blattler, W.A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., 66, 4426-4433.
30. Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V. et al. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc.Natl. Acad.Sci. U.S.A., 104, 12982-12987.
31. Wong, S.C., Klein, J.J., Hamilton, H.L., Chu, Q., Frey, C.L., Trubetskoy, V.S., Hegge, J., Wakefield, D., Rozema, D.B., Lewis, D.L. (2012) Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther., 22, 380-390.
32. Jagannath, A., Wood, M.J. (2009) Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol. Biol. Cell, 20, 521-529.
33. Gibbings, D.J., Ciaudo, C., Erhardt, M., Voinnet, O. (2009) Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Natu. Cell Biol., 11, 1143-1149.
34. Saleh, M.C., van Rij, R.P., Hekele, A., Gillis, A., Foley, E., O'Farrell, P.H., Andino, R. (2006) The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat. Cell Biol., 8, 793-802.
35. Ulvila, J., Parikka, M., Kleino, A., Sormunen, R., Ezekowitz, R.A., Kocks, C., Ramet, M. (2006) Double-stranded RNA is internalized by scavenger receptor-mediated endocytosis in Drosophila S2 cells. J. Biol. Chem., 281, 14370-14375.
36. Anderson, P.D., Huizing, M., Claassen, D.A., White, J., Gahl, W.A. (2003) Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum. Genet., 113, 10-17.
37. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V. et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Natu. Biotechnol., 23, 1002-1007.
38. Harris, D.A., Kim, K., Nakahara, K., Vasquez-Doorman, C., Carthew, R.W. (2011) Cargo sorting to lysosome-related organelles regulates siRNA-mediated gene silencing. J. Cell Biol., 194, 77-87.